ImmunoMod

ImmunoMod is a clinical-stage biotechnology company dedicated to developing transformative therapies for diabetes and autoimmune diseases. Spun out from the Medical University of South Carolina, the company focuses on protecting and regenerating pancreatic beta cells to restore endogenous insulin production. Its lead program targets juvenile Type 1 diabetes, specifically aiming to intervene during the early stages of the disease to preserve remaining cell function. ImmunoMod's research is supported by FDA Orphan Drug designations and collaborations with leading pediatric medical centers. The company's approach combines immunology and metabolic science to address the root causes of insulin deficiency.